Medilink Therapeutics is a biotech company focusing on next-generation antibody-drug conjugate Research & development.
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 14, 2022 | Series B | $70M | 5 | LYFE Capital Qiming Venture Partners | — | Detail |
Mar 1, 2021 | Series A | $50M | 3 | Apricot Capital Loyal Valley Capital Qiming Venture Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
LYFE Capital | Yes | Series B |
Qiming Venture Partners | Yes | Series B |
Apricot Capital | Yes | Series A |
Highlight Capital | — | Series B |
Legend Capital | — | Series B |
Loyal Valley Capital | — | Series B |